- $2.45m
- $6.34m
- $11.42m
NASDAQ RESUMED AT 03:45 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:35 PM
NASDAQ RESUMED AT 03:10 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:05 PM
NASDAQ RESUMED AT 09:58 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:53 AM
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:37 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: NEXGEL Appoints Brian Kieser To Replace CEO Adam Levy Effective August 21
Nexgel Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Nexgel Appoints Dave Hazard As Vice President Of Sales For Bionx Surgical
Brief: Nexgel Inc Co And Celularity Enter Amendment No. 1 To License Agreement On April 17, 2026
Brief: Nexgel New Strategic Partner, Sequence Lifescience, Leads Financing With $5.5 Million To Complete Acquisition Of Celularity Degenerative Disease Segment
Brief: Nexgel Inc - Effective As Of Jan 1, 2026 Appoints Adam E. Drapczuk III As Interim CFO - SEC Filing